HROW
Price
$47.10
Change
+$0.95 (+2.06%)
Updated
Sep 26 closing price
Capitalization
1.74B
49 days until earnings call
OGI
Price
$1.69
Change
-$0.06 (-3.43%)
Updated
Sep 26 closing price
Capitalization
226.85M
Interact to see
Advertisement

HROW vs OGI

Header iconHROW vs OGI Comparison
Open Charts HROW vs OGIBanner chart's image
Harrow
Price$47.10
Change+$0.95 (+2.06%)
Volume$1.33M
Capitalization1.74B
Organigram Global
Price$1.69
Change-$0.06 (-3.43%)
Volume$471.31K
Capitalization226.85M
HROW vs OGI Comparison Chart in %
Loading...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HROW vs. OGI commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a StrongBuy and OGI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (HROW: $47.10 vs. OGI: $1.69)
Brand notoriety: HROW and OGI are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HROW: 214% vs. OGI: 59%
Market capitalization -- HROW: $1.74B vs. OGI: $226.85M
HROW [@Pharmaceuticals: Generic] is valued at $1.74B. OGI’s [@Pharmaceuticals: Generic] market capitalization is $226.85M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HROW’s FA Score shows that 1 FA rating(s) are green whileOGI’s FA Score has 1 green FA rating(s).

  • HROW’s FA Score: 1 green, 4 red.
  • OGI’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than OGI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HROW’s TA Score shows that 4 TA indicator(s) are bullish while OGI’s TA Score has 3 bullish TA indicator(s).

  • HROW’s TA Score: 4 bullish, 4 bearish.
  • OGI’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, HROW is a better buy in the short-term than OGI.

Price Growth

HROW (@Pharmaceuticals: Generic) experienced а +6.22% price change this week, while OGI (@Pharmaceuticals: Generic) price change was -6.11% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.18%. For the same industry, the average monthly price growth was +24.24%, and the average quarterly price growth was +67.33%.

Reported Earning Dates

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.18% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($1.74B) has a higher market cap than OGI($227M). HROW YTD gains are higher at: 40.387 vs. OGI (4.969). HROW has higher annual earnings (EBITDA): 32.1M vs. OGI (-959K). HROW has more cash in the bank: 53M vs. OGI (36.8M). OGI has less debt than HROW: OGI (9.15M) vs HROW (231M). HROW (228M) and OGI (224M) have equivalent revenues.
HROWOGIHROW / OGI
Capitalization1.74B227M768%
EBITDA32.1M-959K-3,347%
Gain YTD40.3874.969813%
P/E RatioN/A195.72-
Revenue228M224M102%
Total Cash53M36.8M144%
Total Debt231M9.15M2,525%
FUNDAMENTALS RATINGS
HROW vs OGI: Fundamental Ratings
HROW
OGI
OUTLOOK RATING
1..100
3731
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
40100
SMR RATING
1..100
9589
PRICE GROWTH RATING
1..100
3843
P/E GROWTH RATING
1..100
101
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HROW's Valuation (85) in the Pharmaceuticals Other industry is in the same range as OGI (87) in the null industry. This means that HROW’s stock grew similarly to OGI’s over the last 12 months.

HROW's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for OGI (100) in the null industry. This means that HROW’s stock grew somewhat faster than OGI’s over the last 12 months.

OGI's SMR Rating (89) in the null industry is in the same range as HROW (95) in the Pharmaceuticals Other industry. This means that OGI’s stock grew similarly to HROW’s over the last 12 months.

HROW's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as OGI (43) in the null industry. This means that HROW’s stock grew similarly to OGI’s over the last 12 months.

OGI's P/E Growth Rating (1) in the null industry is in the same range as HROW (10) in the Pharmaceuticals Other industry. This means that OGI’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HROWOGI
RSI
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
77%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 5 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAUGF0.04N/A
+11.11%
AERO ENERGY LTD.
SWDBY30.050.72
+2.45%
Swedbank AB
SOBS29.900.45
+1.53%
Solvay Bank (NY)
CBUMY30.41N/A
N/A
China National Buildings Material
SRTSF16.96N/A
N/A
Sarantis SA